Myelodysplastic syndromes: dissecting the heterogeneity

Editorial

Peter L Greenberg. J Clin Oncol. 2011.

. 2011 May 20;29(15):1937-8.

doi: 10.1200/JCO.2011.35.2211. Epub 2011 Apr 25.

No abstract available

Comment on

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G, Hedlund A, Hast R, Schlegelberger B, Porwit A, Hellström-Lindberg E, Mufti GJ. Jädersten M, et al. J Clin Oncol. 2011 May 20;29(15):1971-9. doi: 10.1200/JCO.2010.31.8576. Epub 2011 Apr 25. J Clin Oncol. 2011. PMID: 21519010
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.
Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E. Schanz J, et al. J Clin Oncol. 2011 May 20;29(15):1963-70. doi: 10.1200/JCO.2010.28.3978. Epub 2011 Apr 25. J Clin Oncol. 2011. PMID: 21519021 Free PMC article.